At the news
? BULLISHIMPACT 8/10 8-K filed Apr 27, 2026 at 08:45 ET
Biogen completed its acquisition of Amicus Therapeutics for $4.8 billion in an all-cash transaction, funding the deal through a $2.8 billion term loan package and previously issued notes. The acquisition adds Fabry and Pompe disease treatments to Biogen's portfolio, strengthening its rare disease focus.
- Completed acquisition of Amicus Therapeutics for $4.8 billion in all-cash transaction
- Acquired Galafold (Fabry disease) and Pombiliti + Opfolda (Pompe disease) treatments
- Financed through $2.0 billion Term Loan B, $800 million Term Loan A, and $850 million 2034 Notes
- Existing credit agreement was repaid and terminated
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access